| Ident. | Authors (with country if any) | Title |
|---|
| 000710 |
Jeban Ganesalingam [Royaume-Uni] ; Peter Bain [Royaume-Uni] | Apomorphine-Induced Necrotic Ulcers |
| 000711 |
Estelle Dellapina [France] ; Angélique Gerdelat-Mas [France] ; Fabienne Ory-Magne [France] ; Laure Pourcel [France] ; Monique Galitzky [France] ; Fabienne Calvas [France] ; Marion Simonetta-Moreau [France] ; Claire Thalamas [France] ; Pierre Payoux [France] ; Christine Brefel-Courbon [France] | Apomorphine Effect on Pain Threshold in Parkinson's Disease: A Clinical and Positron Emission Tomography Study |
| 000928 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Cesaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible Sublingual Piribedil to Abort OFF Episodes: A Single Dose Placebo-Controlled, Randomized, Double-Blind, Cross-Over Study |
| 000C13 |
Santiago Perez-Lloret [France] ; Emmanuelle Bondon-Guitton [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France] | Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database |
| 000C68 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound Treatment of Cutaneous Side-Effects of Infused Apomorphine : A Randomized Controlled Pilot Study |
| 000C86 |
Julia Vaamonde [Espagne] ; José M. Flores [Espagne] ; Roberto Weisser [Espagne] ; Ramon Ibanez [Espagne] ; José A. Obeso [Espagne] | The Duration of the Motor Response to Apomorphine Boluses Is Conditioned by the Length of a Prior Infusion in Parkinson's Disease |
| 001273 |
Pedro J. Garcia Ruiz ; Angel Sesar Ignacio ; Begona Ares Pensado ; Alfonso Castro Garcia ; Fernando Alonso Frech ; Mercedes Alvarez Lopez ; José Arbelo Gonzalez ; Joan Baiges Octavio ; Juan Andrés Burguera Herandez ; Matilde Calopa Garriga ; Dulce Campos Blanco ; Belén Castano Garcia ; Manuel Carballo Cordero ; José Chacon Pena ; Anna Espino Ibanez ; Aranzazu Gorospe Onisalde ; Santiago Gimenez-Roldan ; Pilar Granes Ibanez ; Jorge Hernandez Vara ; Ramon Ibanez Alonso ; Félix Javier Jimenez Jimenez ; Jerzy Krupinski ; Jaime Kulisevsky Bojarsky ; Inés Legarda Ramirez ; Elena Lezcano Garcia ; Juan Carlos Martinez-Castrillo ; Dolores Mateo Gonzalez ; Francesc Miquel Rodriguez ; Pablo Mir Rivera ; Elena Munoz Fargas ; José Obeso Inchausti ; Jesus Olivares Romero ; José Olive Plana ; Pilar Otermin Vallejo ; Berta Pascual Sedano ; Victor Perez De Colosia Rama ; Isabel Perez Lopez-Fraile ; Albert Planas Cornes ; Victor Puente Periz ; Maria Cruz Rodriguez Oroz ; Dolores Sevillano Garcia ; Pilar Solis Perez ; José Suarez Munoz ; Julia Vaamonde Gamo ; Caridad Valero Merino ; Francesc Valldeoriola Serra ; José Miguel Velazquez Perez ; Rosa Yanez Bana ; Ivana Zamarbide Capdepon | Efficacy of Long-Term Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease with Motor Fluctuations : A Multicenter Study |
| 001470 |
Carmine Vitale [Italie] ; Stefano Marconi [Italie] ; Luigi Di Maio [Italie] ; Giuseppe De Michele [Italie] ; Katia Longo [Italie] ; Vincenzo Bonavita [Italie] ; Paolo Barone [Italie] | Short-Term Continuous Infusion of Apomorphine Hydrochloride for Treatment of Huntington's Chorea : A Double Blind, Randomized Cross-Over Trial |
| 001B03 |
Angela Deutschl Nder [Allemagne] ; Friedrich Asmus [Allemagne] ; Elena Marelli [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Gasser [Allemagne] ; Kai Botzel [Allemagne] | Excellent response to apomorphine in parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication |
| 001E71 |
Svenja Happe [Allemagne] ; Martin Sommer [Allemagne] ; Johannes Meller [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Walter Paulus [Allemagne] | Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder |
| 001E89 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease : A prospective study using single-dose challenges |
| 001F77 |
Lorenzo Priano [Italie] ; Gianni Albani [Italie] ; Andrea Brioschi [Italie] ; Sara Calderoni [Italie] ; Leonardo Lopiano [Italie] ; Mario Rizzone [Italie] ; Roberta Cavalli [Italie] ; Maria Rosa Gasco [Italie] ; Francesco Scaglione [Italie] ; Franco Fraschini [Italie] ; Bruno Bergamasco [Italie] ; Alessandro Mauro [Italie] | Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's Disease |
| 002006 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study |
| 002112 |
Svenja Happe [Allemagne] ; Tobias Tings [Allemagne] ; Kathrin Helmschmied [Allemagne] ; Karin Neubert [Allemagne] ; Wolfgang Wuttke [Allemagne] ; Walter Paulus [Allemagne] ; Claudia Trenkwalder [Allemagne] | Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease |
| 002199 |
Montse Alegret [Espagne] ; Francesc Valldeoriola [Espagne] ; Mjosé Marti [Espagne] ; Manuela Pilleri [Espagne] ; Carme Junque [Espagne] ; Jordi Rumia [Espagne] ; Eduardo Tolosa [Espagne] | Comparative cognitive effects of Bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease |
| 002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002777 |
Guillermo Paradiso [Canada] ; Farooq Khan [Canada] ; Robert Chen [Canada] | Effects of apomorphine on flexor reflex and periodic limb movement |
| 002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
| 002858 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients |
| 002881 |
Han-Cheng Wang [Taïwan] ; YOLOUNG HSIEH [Taïwan] | Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 002B13 |
S. A. Factor [États-Unis] ; D. L. Brown [États-Unis] ; E. S. Molho [États-Unis] | Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease |
| 002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
| 002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002D32 |
A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
| 002E02 |
F. Stocchi [Italie] ; C. Farina [Italie] ; G. Nordera [Italie] ; S. Ruggieri [Italie] | Implantable venous access system for apomorphine infusion in complicated Parkinson's disease |
| 002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
| 002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
| 002E80 |
W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; M. Almaguer [États-Unis] ; Joseph Jankovic [États-Unis] | A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease |
| 002F10 |
T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 003053 |
M. Merello [Argentine] ; A. Cammarota [Argentine] ; M. I. Nouzeilles [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test |
| 003079 |
J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003080 |
M. Gassen [Allemagne] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003081 |
M. Gassen [Israël] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003097 |
R. B. Jr Dewey [États-Unis] ; D. M. Maraganore [États-Unis] ; J. E. Ahlskog [États-Unis] ; J. Y. Matsumoto [États-Unis] | A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease |
| 003311 |
F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003376 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 003386 |
T. E. Eichhorn [Allemagne] ; T. Gasser [Allemagne] ; N. Mai [Allemagne] ; C. Marquardt ; G. Arnold [Allemagne] ; J. Schwarz [Allemagne] ; W. H. Oertel [Allemagne] | Computational analysis of open loop handwriting movements in Parkinson's disease : A rapid method to detect dopamimetic effects |
| 003421 |
T. Van Laar [Pays-Bas] ; C. Neef [Pays-Bas] ; M. Danhof [Pays-Bas] ; K. I. Roon [Pays-Bas] ; R. A. C. Roos [Pays-Bas] | A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease |
| 003462 |
T. Van Laar [Pays-Bas] ; E. N. H. Jansen ; C. Neef ; M. Danhof ; R. A. C. Roos | Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease : a study of five different suppositories |
| 003463 |
S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique] | Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans |
| 003527 |
S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward | Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance |
| 003677 |
A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern | Subcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years |
| 003739 |
L. Schelosky [Allemagne] ; J. Hierholzer ; J. Wissel ; M. Cordes ; Werner Poewe [Autriche] | Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT |
| 003754 |
U. Bonuccelli [Italie] ; P. Piccini [Italie] ; P. Del Dotto [Italie] ; G. Rossi ; G. U. Corsini ; A. Muratorio [Italie] | Apomorphine test for dopaminergic responsiveness: a dose assessment study |
| 003761 |
M. Vidailhet [France] ; C. Bouchard [France] ; P. J. Jedynak [France] ; M. Serdaru [France] | Acute and long-term response to apomorphine in cranial dystonia |
| 003800 |
J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
| 003807 |
S. Przedborski [Belgique] ; A. Liard ; J. Hildebrand | Induction of mania by apomorphine in a depressed Parkinsonian patient |
| 003904 |
S. T. Gancher ; J. G. Nutt ; W. R. Woodward | Absorption of apomorphine by various routes in parkinsonism |
| 003997 |
P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. Shorvon | Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine |
